Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2017 | Achieving deep responses in previously treated CLL patients

Danielle Brander • 12 May 2017
iwCLL 2017
Chronic Lymphocytic Leukemia Rituximab Venetoclax

Danielle Brander, MD from Duke University School of Medicine, Durham, NC discusses the latest updates from the Phase Ib clinical trial, NCT01682616, investigating the combination of venetoclax and rituximab in chronic lymphocytic leukemia (CLL) patients who have previously received treatment. This trial looked specifically at the safety of the combination therapy and at markers of efficacy. At the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY, Dr Brander presented data on patients who had a deep response to the treatment and could thus stop treatment.

More from Danielle Brander

1:49
The management of Richter's transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023
1:13
Exciting updates in CLL: advancing treatment for patients with double-refractory disease
Danielle Brander • 8 Dec 2023
1:46
Managing the side effects associated with BTKi treatment for CLL
Danielle Brander • 8 Dec 2023
2:06
Unmet need: CLL patients intolerant to novel therapies
Danielle Brander • 22 Sep 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals